A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
Clinical trial NCT01412515 · TERMINATED
Trial details
- NCT number
- NCT01412515
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-06-01
- Primary completion
- 2011-05-01
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.